BioSpace News Archive

Rare disease is disorder which affects a small percentage of total population. In last few years, there has been increased interest among pharmaceutical companies for the development of novel orphan drugs against rare diseases.

Rising cases of surgical procedures across the world, advancement in technology and medical practices, increasing fund towards the healthcare system from government, growth in the research for more advanced surgical practices, are key factors contributing to high CAGR of surgical sealants & adhesives during forecast period.

As COVID-19 infections continue to soar across Washington and the Seattle area, GS Labs has experienced a sustained surge in patients seeking rapid tests to determine their current infection status.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced three-month results from an on-label, prospective, multi-center study 1 showing meaningful pain relief using DTM™.

Felix Biotechnology today announced it signed a partnership with AnimalBiome, a leader in pet health and wellness, to develop new solutions to address diarrhea in pets.

China SXT Pharmaceuticals, Inc. announced today that it develops and commercializes the Kuihuapan After-Soaking-Oral TCMP and Zhudanfen Directly-Oral TCMP products.

Gaumard Scientific Co., an industry leader of simulation technology for healthcare education and training, today announced that HAL® S5301, the world’s most advanced multidisciplinary patient simulator, will be introduced at the International Meeting on Simulation in Healthcare (IMSH), January 15-19, at the Los Angeles Convention Center, booth #311.

Mednow Inc. is pleased to announce that the Company has partnered with PACE Consulting Benefits and Pensions Ltd. and PACE Consulting MGA Services Inc. (“ PACE ”) pursuant to a marketing services agreement (the “Agreement”).

The execution demonstrates senior management team’s tremendous confidence in the Company’s innovative globally competitive pipeline and long-term growth prospects.

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received positive feedback from the U.S. Food and Drug Administration (U.S. FDA) at its pre-Investigational New Drug (pre-IND) meeting for its investigation of NP-120 (Ifenprodil) for the treatment of chronic cough.